To access the session recording, navigate to the content tab and click the view video button. 

Session Schedule

Find a specific presentation in the course by navigating to the timestamp indicated below

0:00:00
Vibrance-1: A Randomized Phase 2 Study Evaluating Safety and Efficacy of the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680) in Patients with Narcolepsy Type 1
Giuseppe Plazzi (Italy)

0:13:50
Improvement in the Severity of Narcolepsy Symptoms and Fatigue in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
Yves Dauvilliers (France)

0:24:50
Improvement in Patient-reported Cognitive Functioning in Patients with Narcolepsy Type 1 Treated with the Orexin 2 Receptor Agonist Alixorexton (ALKS 2680)
Giuseppe Plazzi (Italy)

0:35:00
The First Light: Efficacy and Safety of a Multi-Dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1
Emmanuel Mignot (United States)

0:47:50
The Radiant Light: Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1
Yves Dauvilliers (France)

1:01:25
Effect of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) on the Severity of Symptoms in Individuals With Narcolepsy Type 1: Results From Two Phase 3 Studies
Lucie Barateau (France)

1:14:45
Effect of the Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) on Quality of Life in Individuals with NT1 over 12 weeks
Sheila Sivam (Australia)